Effect Sildenafil and Estradiiol Valerate on Endometrial Thickness in Infertile Women

• Status: Completed
• Trial end date: 2018-07-30
• Target enrollment: 0
• Participant gender: Female

Summary

The endometrium is a dynamic tissue that responds to changing hormonal signals throughout the cycle. The changes in the endometrial composition are expressed in alteration in gene expression, micro architectural morphological changes as well as in protein and hormone secretion. These factors combine together to construct the "window of implantation" a short period of time during the luteal phase in which the endometrium is receptive.

Thin endometrium is associated with a low pregnancy rate. Endometrial thickness 7 mm in the pre-ovulatory phase is widely accepted to be cut-off of thin endometrium.

for that the aim of this study is to compare the effect of sildenafil-estrogen combination to estrogen alone on endometrium thickness in infertile women. Half of the patients will receive estrogen ( estradiol valerate ) and the other half will receive combination of sildenafil-estrogen .

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Polyestradiol phosphate; Sildenafil Citrate

Criteria

Inclusion Criteria:

1. Patients having ovulatory infertility.

2. Age: 20-35 years old.

3. BMI less than 30 kg/m2

Exclusion Criteria:

1. Women who have any congenital uterine anomaly (e.g., unicornuate uterus or infantile uterus) or acquired deformities of the uterine cavity that interfere with embryo implantation (as Asherman Syndrome).

2. Women who have any tubal factor that relates to infertility (e.g., tubal adhesion or previous ectopic pregnancy).

3. Women who have contraindication for estrogen treatment (e.g., history of stroke, DVT and Benign liver disease).

4. Women who have male factor for infertility (e.g., azoospermia, teratospermia).